Liraglutide for Adolescents with Obesity.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Exploring the multifaceted roles of GLP-1 receptor agonists; a comprehensive review.Frontiers in clinical diabetes and healthcare · 2025
   Review
2. [Comparison of therapeutic effect of metformin hydrochloride/vildagliptin and liraglutide on type 2 diabetes mellitus in obese patients].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2023
   Article
3. Efficacy of Liraglutide in Obesity in Children and Adolescents: Systematic Review and Meta-Analysis of Randomized Controlled Trials.Children (Basel, Switzerland) · 2023
   Review

Corrections and comments

• Commented on by
  Liraglutide for Adolescents with Obesity. Reply.2020
• Comment on
  A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity.2020

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as